DUPIXENT: First and Only Treatment of Its Kind

DUPIXENT is the first and only biologic treatment for patients aged 12 years and older with uncontrolled moderate-to-severe atopic dermatitis to inhibit the signaling of IL-4 and IL-13, Type 2 cytokines.1,2

  • IL-4 and IL-13 signaling contribute to perpetuating underlying Type 2 inflammation1-5

A Dual Biologic Inhibitor of IL-4 and IL-13 Signaling, Administered Via Injection2

  • Immunosuppressive agents may inhibit multiple pathways5,7

See How it Works

Identifying Patients With Uncontrolled Moderate-to-Severe Atopic Dermatitis

When topical prescription therapies are not enough, consider DUPIXENT to help your
appropriate patients who are struggling to control their disease.2,7

Identify Patients

Image of an actual patient with atopic dermatitis. Not a clinical trial patient.

Frequently Asked
Questions
Have questions? Get answers to some of
the most commonly asked questions.
Get Answers
Dosing and Administration Thinking about prescribing
DUPIXENT? Find the information you
need to get started.
Start Now
Connect With a Rep Have questions about DUPIXENT? Get
answers from a representative.
Request a Visit
References:
  1. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
  2. DUPIXENT Prescribing Information.
  3. Kaiko G, Horvat J, Beagley K, et al. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology. 2008;123(3):326-338.
  4. Guttman-Yassky E, Bissonnette R, Ungar B. et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155-172.
  5. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011;127(3):1420-1432.
  6. Schwartz D, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25-36.
  7. Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate-to-severe atopic dermatitis. J Dermatol. 2018;45(2):150-157.